Study of 6.2 million patients by Kaiser Permanente and CDC researchers will continue for 2 years.
OAKLAND, Calif. — Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 vaccines.
The study published September 2 in JAMA reports the first comprehensive findings of the Vaccine Safety Datalink (VSD), which studies patient records for 12 million people in 5 Kaiser Permanente service regions along with HealthPartners in Minneapolis, the Marshfield Clinic in Wisconsin, and Denver Health. The work is supported by the Centers for Disease Control and Prevention (CDC).
“These results from our safety surveillance are reassuring,” said lead author Nicola Klein, MD, PhD, director of the Kaiser Permanente Vaccine Study Center and principal investigator of the Vaccine Safety Datalink’s COVID-19 rapid cycle analysis.
“The world is relying on safe and effective vaccines to bring an end to the COVID-19 pandemic. The Vaccine Safety Datalink is ideally suited to carry out this important surveillance and we will continue to monitor the safety of all vaccines that protect against COVID-19,” added Dr. Klein, who is also a senior research scientist with the Kaiser Permanente Division of Research.
The study reported findings from mid-December 2020 through June 26, 2021. Some of the early findings had been summarized previously and reported at public meetings of the CDC’s Advisory Committee on Immunization Practices, though the JAMA article is the VSD’s first comprehensive report of its safety surveillance of the Pfizer and Moderna mRNA vaccines.
The analyses compared specific health events among all COVID-19 mRNA-vaccinated people during the first 3 weeks after inoculation with health events among similar types of patients during the 3 to 6 weeks after mRNA vaccination. The total number of people evaluated was 6.2 million for the first dose of either mRNA vaccine and 5.7 million for the second dose.
The design is meant to compare patients who are as similar to one another as possible to reduce the number of factors that could complicate the results. The authors added a comparison group of unvaccinated patients in a supplemental analysis.
The researchers examined 23 potential health effects, chosen because they had been included in previous vaccine studies, were of particular concern as an effect of COVID-19, were noted during the COVID-19 clinical trials, or were added after public health officials reported increased cases among vaccinated people. Outcomes tracked included neurological disorders such as encephalitis and myelitis, seizures, and Guillain-Barré syndrome; cardiovascular problems such as acute myocardial infarction, stroke, and pulmonary embolism; and others such as Bell’s palsy, appendicitis, anaphylaxis, and multisystem inflammatory syndrome.
Patient medical records were searched electronically and analysts carried out chart reviews of specific health outcomes to verify the medical problem and to assess whether it started before or after vaccination.
Vaccine Safety Datalink researchers then applied statistical analysis to determine whether the number of incidents was above a certain threshold, or “signal.” They concluded that none of the target health outcomes reached the signal, though for some outcomes the findings were less precise because of small numbers of cases. The authors said VSD safety surveillance is ongoing, which will increase the precision of estimates for those outcomes.
The study authors highlighted their findings about cases of confirmed myocarditis and pericarditis among young individuals, as that has become an outcome of concern. The VSD study identified 34 such cases in patients 12 to 39 years old; 85% of them were male and 82% hospitalized (for a median of 1 day), and nearly all recovered by the time the chart review took place. The authors calculated that among patients 12 to 39 years old, there is a risk of 6.3 additional myocarditis cases per million doses during the first week after vaccination. Other research has calculated a significantly higher risk of myocarditis from COVID-19 than from the vaccine.
“The results of this study are a great example of how seriously CDC takes vaccine safety, and how thorough and transparent we are in our safety monitoring efforts,” said Tom Shimabukuro, MD, leading vaccine safety for the COVID-19 response and the deputy director of CDC’s Immunization Safety Office. “It is our top priority to do the science and communicate quickly and clearly with healthcare providers and the public, as COVID-19 vaccines continue to undergo the most intensive safety monitoring in U.S. history. Getting vaccinated remains the best way to protect yourself and your loved ones against a virus that has taken millions of lives.”
The VSD’s rapid-cycle analysis for the mRNA COVID-19 vaccines will continue tracking newly vaccinated patients for at least 2 years. The VSD, established in 1990 and led by the CDC, Kaiser Permanente, and other health care systems, is the nation’s premier active surveillance system for vaccine safety.
The study was funded by the CDC.
About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America’s leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve approximately 12.5 million members in 8 states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists, and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery, and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education, and the support of community health.
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Article Publication Date